Intriguingly, and of relevance to this work, the addition of PPARα agonistic activity to PPARγ, PPARγ, to PPARδ agonists has led to a higher safety profile, leading to their development for use in many diseases, including type 2 diabetes, dyslipidemia, and non-alcoholic fatty liver disease29. The gene discussed is PPARA; the disease is metabolic syndrome.